Quick Answer
Aura Biosciences, Inc. reported Research And Development Expense of $90.30 million for the year ending 2025.
- Aura Biosciences, Inc. showed an increase of +23.2% in Research And Development Expense from 2024 to 2025.
- This data is from Aura Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $2.85 million | Q1 2021: $4.19 million | Q2 2021: $6.63 million | Q3 2021: $6.37 million | Q1 2022: $8.28 million | Q2 2022: $9.51 million | Q3 2022: $11.29 million | Q1 2023: $14.41 million | Q2 2023: $15.12 million | Q3 2023: $15.43 million | Q1 2024: $17.05 million | Q2 2024: $16.88 million | Q3 2024: $17.04 million | Q1 2025: $23.34 million | Q2 2025: $22.88 million | Q3 2025: $22.18 million.
- Over the full 6 years of available data (2020 to 2025), Aura Biosciences, Inc.'s Research And Development Expense has grown by 400.5%.
- Historical annual values: Fiscal year 2025: $90.30 million | Fiscal year 2024: $73.30 million | Fiscal year 2023: $65.23 million | Fiscal year 2022: $42.24 million | Fiscal year 2021: $25.16 million | Fiscal year 2020: $18.04 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: